Harrow Inc. (NASDAQ:HROW) reported first-half 2026 revenue of approximately $115 million, falling short of management expectations due to pricing changes tied to its VEVYE dry eye treatment. The shortfall sets up a demanding back half as the company reiterated its full-year guidance of $350 million to $365 million—a target that requires the second half alone to produce roughly $235 million to $250 million in revenue.

Market Context

The ophthalmology sector has seen mixed performance this year as companies navigate reimbursement headwinds and pricing pressures. Harrow's first-half miss comes against a backdrop where specialty pharma investors have grown increasingly focused on margin expansion and path to profitability rather than top-line growth alone. The company operates in the competitive dry eye, cataract surgery, and retina disease markets, segments that have seen increased consolidation activity.

Analysis

The bull case rests on accelerating momentum across Harrow's three core products. IHEEZO delivered a record 65,477 units of quarterly demand despite losing pass-through reimbursement for cataract surgery on April 1—a 44% sequential increase and 34% year-over-year jump. The product added 62 first-time ordering accounts in the quarter, its strongest new-account quarter since launch. Net pricing improved approximately 25% starting July 1, pushing gross margins above 90%, suggesting the reimbursement loss is being offset by better unit economics.

VEVYE posted prescription growth of 21% sequentially, outpacing the broader branded dry eye market's 14% expansion while growing its prescriber base by 15%. Quarterly revenue reached $29.4 million, up nearly 58% year-over-year, even as management reduced copay card utilization to drive higher average selling prices. The product's share of the branded dry eye market climbed to 14.6%, up from 14% in March and 7.8% a year earlier—demonstrating that Harrow can simultaneously grow faster than the category while improving unit economics.

TRIESENCE posted record demand of 14,529 units, a 162% year-over-year increase, with over half of that volume now coming from ocular surgery rather than its traditional retina base. The company tripled its surgical sales team during the quarter to capitalize on this shift.

The bear case centers on the math behind guidance. CFO Andrew Boll acknowledged that 'we recognize the magnitude of the second-half ramp,' leaving little margin for error across IHEEZO's pricing gains, VEVYE's new business rules implementation, or TRIESENCE's surgical buildout to come in soft. Adjusted EBITDA remained negative at $1.2 million for the quarter, and the pending TYRVAYA acquisition adds roughly $20 million in annualized SG&A once Harrow integrates the sales representatives it is acquiring from Viatris—ahead of any meaningful revenue contribution this year.

Key Numbers

- First-half 2026 revenue: ~$115 million (below management expectations)

- Full-year guidance maintained: $350 million to $365 million

- Second-half revenue required: $235 million to $250 million

- IHEEZO quarterly demand: 65,477 units (+44% sequential, +34% year-over-year)

- IHEEZO ordering accounts: 224 (+32% year-over-year), including 62 first-time orders

- IHEEZO net pricing improvement: ~25% (effective July 1)

- VEVYE quarterly revenue: $29.4 million (+58% year-over-year)

- VEVYE prescription growth: +21% sequential vs. market's +14%

- VEVYE branded dry eye market share: 14.6% (from 7.8% a year ago)

- TRIESENCE demand: 14,529 units (+162% year-over-year); 54% from ocular surgery

- Adjusted EBITDA: negative $1.2 million for the quarter

- TYRVAYA expected 2027 revenue contribution: >$30 million

- Cash and equivalents: $83.9 million

What to Watch

Investors will monitor whether VEVYE's market share gains continue accelerating as Harrow reduces copay card support and relies more on net pricing improvements. IHEEZO's ability to sustain demand without pass-through reimbursement will be critical, particularly as the July 1 price increase takes full effect across the customer base. TRIESENCE's surgical expansion represents a new growth vector that could offset weakness elsewhere if execution holds. The TYRVAYA acquisition is expected to close in 2026 and contribute meaningfully only beginning in 2027, meaning the $30 million upfront payment and integration costs will weigh on profitability this year without corresponding revenue offsets.

Harrow's ability to bridge a roughly $120-135 million revenue gap between its first-half actuals and what it needs in the second half will define the investment thesis for the back half of 2026. Any deceleration in IHEEZO ordering, VEVYE prescription trends, or TRIESENCE surgical conversion would put full-year guidance at risk.